Regulation of DNA topoisomerase IIα stability by the ECV ubiquitin ligase complex

Biochemical and Biophysical Research Communications

Volumn 389, Issue 1, 2009, Pages 5-9

  Yun, Jisoo ^a   Kim, Yong Il ^a   Tomida, Akihiro ^b   Choi, Cheol Hee ^a,c  

^a Chosun University   (South Korea)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c Chosun University College of Medicine   (South Korea)

Author keywords

Cullin 2; DNA topoisomerase II ; Elongin B C; GRDD; UPS; VHL

Indexed keywords

CULLIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ELONGIN BC; ELONGIN BC CULLIN 2 VON HIPPEL LINDAU PROTEIN COMPLEX; ELONGIN C; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL STRAIN HEK293; DELETION MUTANT; ENZYME DEGRADATION; ENZYME STABILITY; GENE DELETION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; ANTIGENS, NEOPLASM; CELL LINE; CULLIN PROTEINS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME STABILITY; HUMANS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 70349146204     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.08.066     Document Type: Article

References (25)

1. Wang J.C. DNA topoisomerase II. Annu. Rev. Biochem. 65 (1996) 635-692
2. Yun J., Tomida A., Nagata K., and Tsuruo T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol. Res. 7 (1995) 583-590
3. Shen J.W., Subjeck J.R., Lock R.B., and Ross W.E. Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol. Cell. Biol. 9 (1989) 3284-3291
4. Froelich-Ammon S.J., and Osheroff N. Topoisomerase poison: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270 (1995) 21429-21432
5. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58 (1998) 1408-1416
6. Tomida A., and Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 14 (1999) 169-177
7. Dingemans A.M., Pinedo H.M., and Giaccone G. Clinical resistance to topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400 (1998) 275-288
8. Kim H.D., Tomida A., Ogiso Y., and Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIα by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J. Cell. Physiol. 180 (1999) 97-104
9. Ogiso Y., Tomida A., Lei S., Omura S., and Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60 (2000) 2429-2434
10. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 25-479
11. Nakajima T., Morita K., Ohi N., Arai T., Nozaki N., Kikuchi A., Osaka F., Yamao F., and Oda K. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J. Biol. Chem. 271 (1996) 24842-24849
12. Huibregtse J.M., Schneffner M., Beaudenon S., and Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 92 (1995) 2563-2567
13. Zachariae W., and Nasmyth K. Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev. 13 (1999) 2039-2058
14. Bai C.P., Hofmann K., Ma L., Goebl M., Harper J.W., and Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86 (1996) 263-274
15. Feldman R.M.R., Correll C.C., Kaplan K.B., and Deshaies R.J. A complex of Cdc4p, Skp1p, and Cdc53p/Cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91 (1997) 221-230
16. 2 sensing. Science 292 (2001) 464-468
17. Yun J., Tomida A., Andoh T., and Tsuruo T. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIα and MPN domain of Jab1/CSN5. J. Biol. Chem. 279 (2004) 31296-31303
18. Zhang H.F., Tomida A., Koshimizu R., Ogiso Y., Lei S., and Tsuruo T. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res. 64 (2004) 1114-1121
19. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y., Garrett K.P., Conaway R.C., Conaway J.W., Linehan V.M., and Klausner R.D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269 (1995) 1402-1406
20. Kibel A., Iliopoulos O., DeCaprio J.A., and Kaelin Jr. W.G. Binding of von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 (1995) 1444-1446
21. Stebbins C.E., Kaelin Jr. W.G., and Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284 (1999) 455-461
22. Conaway J.W., Kamura T., and Conaway R.C. The Elongin BC complex and von Hippel-Lindau tumor suppressor protein. Biochim. Biophys. Acta 1377 (1998) M49-M54
23. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., Conaway J.W., and Nakayama K.I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligase. Genes Dev. 18 (2004) 3055-3065
24. Ogiso Y., Tomida A., Kim H.D., and Tsuruo T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem. Biophys. Res. Commun. 258 (1999) 448-452
25. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992